NCT01308047

Brief Summary

The purpose of this study is to compare the non-inferiority between Heavy Levobupivacaine with Enantiomeric Excess of 50% and Heavy Racemic Bupivacaine During Spinal Anesthesia for Orthopedic Procedures in the Lower Limbs.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

2 active sites

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 23, 2011

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 3, 2011

Completed
Last Updated

March 26, 2014

Status Verified

March 1, 2014

First QC Date

February 23, 2011

Last Update Submit

March 25, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • Time of latency for sensory block at T10 dermatome.

    Evaluate the sensory block at T10 after the anesthetic injection through sensory stimulation by needle.

    +/- 40 min after injection

Secondary Outcomes (8)

  • Sensory block duration

    +/- 3 hours

  • Motor Block Evaluation

    +/- 30 min

  • Maximum cranial dispersion verifying the largest metamer achieved.

    +/- 45 min

  • Evaluation of the cardiocirculatory and respiratory parameters

    +/- 8 hours

  • Time of regression of motor block by Bromage Scale

    +/- 9 - 10 hours

  • +3 more secondary outcomes

Study Arms (2)

bupivacaine S75:R25

EXPERIMENTAL

3 ml for subarachnoid block

Drug: Bupivacaine

bupivacaine (S50:R50)

ACTIVE COMPARATOR

3 ml subarachnoid block

Drug: Bupivacaine

Interventions

single dose of 15mg by a slow injection rate of 1 ml/s

Also known as: marcaine
bupivacaine (S50:R50)bupivacaine S75:R25

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ASA (American Society of Anesthesiologists) I or ASA II
  • Spinal Anaesthesia for lower limb surgery
  • Patient Consent

You may not qualify if:

  • relative or absolute contraindications for spinal anesthesia
  • history of hypersensitivity to the local anesthetics or components
  • opioids for anesthetic adjuvant
  • spinal lesions, peripheral neuropathies or any other neurologic disorders that leads to changes of sensitivity
  • Body mass index = or \> 35
  • lumbar puncture difficulty
  • ventricular extrasystoles
  • dementia, others loss of cognitive ability
  • difficulty in the spine
  • spinal cord surgery
  • anaphylactic reactions or Stevens-johnson Syndrome
  • polytraumatism
  • alcoholism abuse and use of illicit substance
  • Changes in the blood test
  • Others conditions judged by investigator's opinion

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Hospital Sepaco

São Paulo, São Paulo, Brazil

Location

Irmandade da Santa Casa de Misericórdia de São Paulo

São Paulo, São Paulo, Brazil

Location

MeSH Terms

Interventions

Bupivacaine

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • Ligia Mathias, PhD

    Irmandade da Santa Casa de Misericórdia de São Paulo

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 23, 2011

First Posted

March 3, 2011

Last Updated

March 26, 2014

Record last verified: 2014-03

Locations